Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine

[Guest guest]

Failure of adefovir 20 mg to improve suboptimal response in

lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and

lamivudine

Authors: Viganò, M.1; Lampertico, P.1; Facchetti, F.1; Lunghi, G.2; Colombo,

M.1

Source: Journal of Viral Hepatitis, Volume 15, Number 12, December 2008 , pp.

922-924(3)

Publisher: Blackwell Publishing

Abstract:

Summary. 

Nine patients with lamivudine-resistant chronic hepatitis B infection who had

been treated with adefovir 10 mg/day and had had a suboptimal response but did

not have genotypic resistance to adefovir were treated with high-dose adefovir

(20 mg/day). The response to the increased dose of adefovir was compared with

the response in 15 patients with a suboptimal response who did not receive an

increase in the dose of adefovir. The increase in the dose of adefovir did not

lead to a significant reduction in hepatitis B DNA when compared with patients

maintained on the standard dose. These data suggest that increasing the dose of

adefovir in patients with a suboptimal response does not lead to an improved

response.

Keywords: adefovir dipivoxil; antiviral treatment; HBV DNA; hepatitis B;

lamivudine resistance; suboptimal response

Document Type: Research article

DOI: 10.1111/j.1365-2893.2008.01047.x

Affiliations: 1: “A. M. and A. Migliavacca†Center for Liver Disease, 1st

Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Ospedale

Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan,

Italy 2: Division of Hygiene, IRCCS Fondazione Ospedale Maggiore Policlinico,

Mangiagalli e Regina Elena, Milan, Italy

[Guest guest]

Failure of adefovir 20 mg to improve suboptimal response in

lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and

lamivudine

Authors: Viganò, M.1; Lampertico, P.1; Facchetti, F.1; Lunghi, G.2; Colombo,

M.1

Source: Journal of Viral Hepatitis, Volume 15, Number 12, December 2008 , pp.

922-924(3)

Publisher: Blackwell Publishing

Abstract:

Summary. 

Nine patients with lamivudine-resistant chronic hepatitis B infection who had

been treated with adefovir 10 mg/day and had had a suboptimal response but did

not have genotypic resistance to adefovir were treated with high-dose adefovir

(20 mg/day). The response to the increased dose of adefovir was compared with

the response in 15 patients with a suboptimal response who did not receive an

increase in the dose of adefovir. The increase in the dose of adefovir did not

lead to a significant reduction in hepatitis B DNA when compared with patients

maintained on the standard dose. These data suggest that increasing the dose of

adefovir in patients with a suboptimal response does not lead to an improved

response.

Keywords: adefovir dipivoxil; antiviral treatment; HBV DNA; hepatitis B;

lamivudine resistance; suboptimal response

Document Type: Research article

DOI: 10.1111/j.1365-2893.2008.01047.x

Affiliations: 1: “A. M. and A. Migliavacca†Center for Liver Disease, 1st

Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Ospedale

Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan,

Italy 2: Division of Hygiene, IRCCS Fondazione Ospedale Maggiore Policlinico,

Mangiagalli e Regina Elena, Milan, Italy

[Guest guest]

Failure of adefovir 20 mg to improve suboptimal response in

lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and

lamivudine

Authors: Viganò, M.1; Lampertico, P.1; Facchetti, F.1; Lunghi, G.2; Colombo,

M.1

Source: Journal of Viral Hepatitis, Volume 15, Number 12, December 2008 , pp.

922-924(3)

Publisher: Blackwell Publishing

Abstract:

Summary. 

Nine patients with lamivudine-resistant chronic hepatitis B infection who had

been treated with adefovir 10 mg/day and had had a suboptimal response but did

not have genotypic resistance to adefovir were treated with high-dose adefovir

(20 mg/day). The response to the increased dose of adefovir was compared with

the response in 15 patients with a suboptimal response who did not receive an

increase in the dose of adefovir. The increase in the dose of adefovir did not

lead to a significant reduction in hepatitis B DNA when compared with patients

maintained on the standard dose. These data suggest that increasing the dose of

adefovir in patients with a suboptimal response does not lead to an improved

response.

Keywords: adefovir dipivoxil; antiviral treatment; HBV DNA; hepatitis B;

lamivudine resistance; suboptimal response

Document Type: Research article

DOI: 10.1111/j.1365-2893.2008.01047.x

Affiliations: 1: “A. M. and A. Migliavacca†Center for Liver Disease, 1st

Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Ospedale

Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan,

Italy 2: Division of Hygiene, IRCCS Fondazione Ospedale Maggiore Policlinico,

Mangiagalli e Regina Elena, Milan, Italy

[Guest guest]

Failure of adefovir 20 mg to improve suboptimal response in

lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and

lamivudine

Authors: Viganò, M.1; Lampertico, P.1; Facchetti, F.1; Lunghi, G.2; Colombo,

M.1

Source: Journal of Viral Hepatitis, Volume 15, Number 12, December 2008 , pp.

922-924(3)

Publisher: Blackwell Publishing

Abstract:

Summary. 

Nine patients with lamivudine-resistant chronic hepatitis B infection who had

been treated with adefovir 10 mg/day and had had a suboptimal response but did

not have genotypic resistance to adefovir were treated with high-dose adefovir

(20 mg/day). The response to the increased dose of adefovir was compared with

the response in 15 patients with a suboptimal response who did not receive an

increase in the dose of adefovir. The increase in the dose of adefovir did not

lead to a significant reduction in hepatitis B DNA when compared with patients

maintained on the standard dose. These data suggest that increasing the dose of

adefovir in patients with a suboptimal response does not lead to an improved

response.

Keywords: adefovir dipivoxil; antiviral treatment; HBV DNA; hepatitis B;

lamivudine resistance; suboptimal response

Document Type: Research article

DOI: 10.1111/j.1365-2893.2008.01047.x

Affiliations: 1: “A. M. and A. Migliavacca†Center for Liver Disease, 1st

Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Ospedale

Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan,

Italy 2: Division of Hygiene, IRCCS Fondazione Ospedale Maggiore Policlinico,

Mangiagalli e Regina Elena, Milan, Italy